Alimera Sciences (NASDAQ:ALIM), According to the latest information the short interest in Alimera Sciences, Inc. plummeted by 3.2% or 72,248 shares. The final shorts are 8% of the total floated shares. The positions dropped from 2,286,145 shares on May 31,2016 to 2,213,897 on June 15,2016. According to the per-day average trading of 174,815 shares, the days to cover are 13. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Alimera Sciences (NASDAQ:ALIM): The stock opened at $1.43 on Friday but the bulls could not build on the opening and the stock topped out at $1.48 for the day. The stock traded down to $1.37 during the day, due to lack of any buying support eventually closed down at $1.40 with a loss of -6.04% for the day. The stock had closed at $1.49 on the previous day. The total traded volume was 2,922,620 shares.
The company shares have dropped -68.89% from its 1 Year high price. On Apr 21, 2016, the shares registered one year high at $5.15 and the one year low was seen on Jun 24, 2016. The 50-Day Moving Average price is $1.61 and the 200 Day Moving Average price is recorded at $2.03.
Alimera Sciences (NASDAQ:ALIM) has tumbled 14.11% during the past week and has dropped 9.68% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 12.69%. Alimera Sciences (NASDAQ:ALIM) has underperformed the index by 6.94% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company focuses on diseases affecting the back of the eye, or retina. The Companys commercial product is ILUVIEN, which has been developed to treat diabetic macular edema (DME). ILUVIEN has received marketing authorization in the United States, Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the EU countries, it is indicated for the treatment of vision impairment associated with DME.